Effects of Fostamatinib, an Oral Spleen Tyrosine Kinase Inhibitor, in Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate: Results From a Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study

Michael E Weinblatt; Mark C Genovese; Meilien Ho; Sally Hollis; Krystyna Rosiak-Jedrychowicz; Arthur Kavanaugh; David S Millson; Gustavo Leon; Millie Wang; Désirée Heijde

doi:10.1002/art.38851

Effects of Fostamatinib, an Oral Spleen Tyrosine Kinase Inhibitor, in Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate: Results From a Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study

Michael E Weinblatt, Mark C Genovese, Meilien Ho, Sally Hollis, Krystyna Rosiak-Jedrychowicz, Arthur Kavanaugh, David S Millson, Gustavo Leon, Millie Wang, Désirée Heijde

The University of Manchester

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	3255-3264
Number of pages	10
Journal	Arthritis & Rheumatology (Hoboken)
Volume	66
Issue number	12
DOIs	https://doi.org/10.1002/art.38851
Publication status	Published - 2014

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1002/art.38851

Cite this

Weinblatt, M. E., Genovese, M. C., Ho, M., Hollis, S., Rosiak-Jedrychowicz, K., Kavanaugh, A., Millson, D. S., Leon, G., Wang, M., & Heijde, D. (2014). Effects of Fostamatinib, an Oral Spleen Tyrosine Kinase Inhibitor, in Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate: Results From a Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study. Arthritis & Rheumatology (Hoboken) , 66(12), 3255-3264. https://doi.org/10.1002/art.38851

Weinblatt, Michael E ; Genovese, Mark C ; Ho, Meilien et al. / Effects of Fostamatinib, an Oral Spleen Tyrosine Kinase Inhibitor, in Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate: Results From a Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study. In: Arthritis & Rheumatology (Hoboken) . 2014 ; Vol. 66, No. 12. pp. 3255-3264.

@article{5789aede353f451ca9456f8e8557db63,

title = "Effects of Fostamatinib, an Oral Spleen Tyrosine Kinase Inhibitor, in Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate: Results From a Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study",

author = "Weinblatt, \{Michael E\} and Genovese, \{Mark C\} and Meilien Ho and Sally Hollis and Krystyna Rosiak-Jedrychowicz and Arthur Kavanaugh and Millson, \{David S\} and Gustavo Leon and Millie Wang and D{\'e}sir{\'e}e Heijde",

year = "2014",

doi = "10.1002/art.38851",

language = "English",

volume = "66",

pages = "3255--3264",

journal = "Arthritis \& Rheumatology (Hoboken) ",

issn = "2326-5205",

publisher = "John Wiley \& Sons Ltd",

number = "12",

}

Weinblatt, ME, Genovese, MC, Ho, M, Hollis, S, Rosiak-Jedrychowicz, K, Kavanaugh, A, Millson, DS, Leon, G, Wang, M & Heijde, D 2014, 'Effects of Fostamatinib, an Oral Spleen Tyrosine Kinase Inhibitor, in Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate: Results From a Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study', Arthritis & Rheumatology (Hoboken) , vol. 66, no. 12, pp. 3255-3264. https://doi.org/10.1002/art.38851

Effects of Fostamatinib, an Oral Spleen Tyrosine Kinase Inhibitor, in Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate: Results From a Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study. / Weinblatt, Michael E; Genovese, Mark C; Ho, Meilien et al.
In: Arthritis & Rheumatology (Hoboken) , Vol. 66, No. 12, 2014, p. 3255-3264.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Effects of Fostamatinib, an Oral Spleen Tyrosine Kinase Inhibitor, in Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate: Results From a Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study

AU - Weinblatt, Michael E

AU - Genovese, Mark C

AU - Ho, Meilien

AU - Hollis, Sally

AU - Rosiak-Jedrychowicz, Krystyna

AU - Kavanaugh, Arthur

AU - Millson, David S

AU - Leon, Gustavo

AU - Wang, Millie

AU - Heijde, Désirée

PY - 2014

Y1 - 2014

U2 - 10.1002/art.38851

DO - 10.1002/art.38851

M3 - Article

SN - 2326-5205

VL - 66

SP - 3255

EP - 3264

JO - Arthritis & Rheumatology (Hoboken)

JF - Arthritis & Rheumatology (Hoboken)

IS - 12

ER -

Weinblatt ME, Genovese MC, Ho M, Hollis S, Rosiak-Jedrychowicz K, Kavanaugh A et al. Effects of Fostamatinib, an Oral Spleen Tyrosine Kinase Inhibitor, in Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate: Results From a Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study. Arthritis & Rheumatology (Hoboken) . 2014;66(12):3255-3264. doi: 10.1002/art.38851